DuLac Farmaceutici, an Italian pharmaceutical company, is accelerating its expansion into the U.S. market with the launch of its products on OneLavi.com and its participation in the 2026 ECRM Vitamin, Weight Management & Sports Nutrition Session, scheduled for September 14-17 in Palm Beach Gardens, Florida. These strategic moves are designed to build on the company's established consumer demand on Amazon and open new retail channels across the United States.
The company views the U.S. as a significant long-term growth market and is pursuing a multi-channel approach that combines its existing Amazon presence, the new e-commerce partnership with OneLavi, and direct engagement with retailers and distributors. Gabriele Bollani, Founder and CEO of DuLac Farmaceutici, emphasized the importance of this phase, stating, "ECRM comes at an important time for DuLac because we are making a major commitment to the U.S. market. Amazon has demonstrated that American consumers are responding to our products, OneLavi gives us another important U.S. channel, and now we are ready to introduce DuLac to major retailers and build the partnerships that can take our expansion to the next level."
DuLac's growth in the U.S. is underpinned by strong consumer feedback on Amazon, where its Arnica Gel 98% has garnered more than 13,000 customer reviews with an average 4.5-star rating, and its Dinaven line has received over 4,000 reviews with a 4.6-star average. The addition of OneLavi as a distribution partner expands the company's reach, allowing more American consumers to access its Made in Italy portfolio.
Participation in the ECRM session adds a business-to-business dimension to DuLac's U.S. strategy. The company will engage in scheduled meetings with buyers from major health, specialty, food, drug, and mass retail channels, presenting its Italian-developed products, pharmaceutical heritage, and advanced manufacturing capabilities. Key products to be highlighted include the high-concentration Arnica Gel 98% range and the Dinaven and Diosmin lines. The objective extends beyond securing additional points of distribution; DuLac aims to establish relationships that will support a broader, more diversified retail presence as it executes its national expansion plan.
DuLac brings over 30 years of pharmaceutical industry expertise and pharmacy-channel experience in Italy to its U.S. efforts. Its product development and manufacturing capabilities include the proprietary Arnica Montana Arricchita™ project, indoor vertical farming, micronized Diosmin MPFF technology, solvent-free Supercritical CO₂ Extraction, and manufacturing under internationally recognized GMP and ISO quality frameworks. This combination of Italian pharmaceutical heritage, research, advanced production technologies, and growing U.S. distribution provides a solid foundation for the company's next stage of growth.
With Amazon already established, OneLavi now live, and scheduled meetings with major retail buyers planned through ECRM, DuLac is transitioning from initial market development to a broader national expansion strategy. The company's goal is to build a diversified U.S. presence across e-commerce, retail, wholesale, and other channels while introducing more American consumers to the DuLac brand and its Italian-developed products.
